Orthofix Medical (NASDAQ:OFIX) Bolsa

Orthofix Medical

Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

GMED

OFIX

Orthofix Medical (OFIX) y Globus Medical (GMED) muestran niveles de RSI por encima de 70. ¿Es momento de vender?

¿Señal de alerta? Estas acciones de salud están sobrecompradas

ALTG

Alterity Therapeutics Limited - American Depositary Shares

ATHE

CARM

CNCK

CRGX

FBNC

MGOL

NAOV

NATR

RNGR

SLXN

TSLA

VREX

XFOR

Meta sube en la preapertura tras superar expectativas. Descubre qué otras acciones están registrando fuertes movimientos hoy.

Acciones de Meta Platforms (META) están cotizando al alza; 20 acciones que se mueven en el premercado de EE.UU.

Movers

ALVO

BBGI

BCAX

ELTX

FOXO

ISPC

JBHT

LYTS

MDXG

NUKK

TMCI

TXNM

VIAV

WILC

Explora los mayores ganadores y perdedores en las operaciones previas al mercado. Descubre qué impulsó estos movimientos destacados.

Las acciones de Versus Systems (VS) aumentan un 71%; 20 acciones que se mueven en el premercado de EE.UU.

Orthofix Medical Inc

Canaccord Genuity analyst Caitlin Burrows maintains Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Buy and maintains $24 price target.

Price Target

Analyst Ratings

Canaccord Genuity Maintains Buy on Orthofix Medical, Maintains $24 Price Target

Roth MKM analyst Jason Wittes reiterates Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Buy and maintains $22 price target.

Reiteration

Roth MKM Reiterates Buy on Orthofix Medical, Maintains $22 Price Target

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) sees FY2025 sales of $818.000 million-$826.000 million vs $847.01 million analyst estimate.

Guidance

Orthofix Medical Sees FY2025 Sales $818.000M-$826.000M vs $847.01M Est

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.05) by 140 percent. This is a 103.39 percent increase over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $215.66 million which beat the analyst consensus estimate of $212.71 million by 1.38 percent. This is a 7.61 percent increase over sales of $200.41 million the same period last year.

Earnings

Earnings Beats

Orthofix Medical Q4 Adj $0.02 Beats $(0.05) Estimate, Sales $215.66M Beat $212.71M Estimate

AHCO

ALLT

ARQT

AXGN

AXON

BASE

BGFV

BLZE

BTDR

BWIN

CART

CAVA

CBLL

CCCS

CECO

CGBD

CHRD

CIFR

CPNG

CPSS

DAWN

DNUT

DOCN

DRVN

ELAN

EXLS

FIHL

FLYW

FSLR

FULC

GPOR

HRMY

HSIC

HURN

HYLN

IART

ICCC

IGIC

IMOS

INGN

INTU

INVX

IPAR

ITRI

IVAC

JACK

JAZZ

KEYS

KNSA

LCID

LGIH

LIVN

LMND

LXFR

MASI

MATX

MFIC

MIDD

MMSI

MPLN

MRVI

NOVT

NXRT

Earnings Scheduled For February 25, 2025

As of Feb. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the<a href="https://www.benzinga.com/topic/rsi"> RSI is above 70</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>. 
Here's the latest list of major overbought players in this sector.
<h3 class="wp-block-heading">Orthofix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>)</h3>
<ul>
<li>Orthofix Medical announced that it will release its fourth quarter and full-year 2024 financial results on Tuesday, Feb. 25, 2025 before the opening bell. The company has a <a href="https://www.benzinga.com/quote/OFIX">52-week high of $20.73</a>.</li>
<li>RSI Value: 77.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>OFIX Price Action: Shares of Orthofix Medical gained 3.1% to close at $18.76 on Tuesday.</li>
</ul>
<h3 class="wp-block-heading">Globus Medical Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>)</h3>
<ul>
<li>On Feb. 3, Interactive Brokers reported a year-over-year increase in daily average revenue trades for January. The company's stock gained around 10% over the past month and <a href="https://www.benzinga.com/quote/GMED">has a 52-week high</a> of $94.93.</li>
<li>RSI Value: 74</li>
<li>GMED Price Action: Shares of Globus Medical fell 0.4% to close at $92.18 on Tuesday.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

Top 2 Health Care Stocks That May Crash In February

Shares of Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/general/social-media/25/01/43322201/meta-platforms-q4-earnings-revenue-beat-eps-beat-daily-actives-up-5-continued-strong-revenue-growth-expected">fourth-quarter sales results</a>.
Meta reported fourth-quarter revenue of $48.39 billion, beating analyst estimates of $47.03 billion. The company reported fourth-quarter earnings of $8.02 per share, beating analyst estimates of $6.77 per share.
Meta shares gained 2.2% to $691.66 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Alterity Therapeutics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) gained 105% to $6.13 in pre-market trading.</li>
<li>NanoVibronix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAOV#NASDAQ">NAOV</a>) rose 54.1% to $0.5853 in pre-market trading.</li>
<li>X4 Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) gained 40.1% to $1.03 in pre-market trading after jumping more than 52% on Wednesday.</li>
<li>MGO Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) gained 21.9% to $0.1240 in pre-market trading after dipping over 38% on Wednesday.</li>
<li>Carisma Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARM#NASDAQ">CARM</a>) gained 18.4% to $0.5980 in pre-market trading.</li>
<li>Alta Equipment Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTG#NYSE">ALTG</a>) rose 14.1% to $8.01 in pre-market trading.</li>
<li>Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) shares jumped 13.1% to $113.66 in pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued FY25 guidance above estimates.</li>
<li>Ranger Energy Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNGR#NYSE">RNGR</a>) gained 10.5% to $19.00 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rose 2.9% to $400.23 in pre-market trading. Tesla reported weaker-than-expected fourth-quarter earnings and sales results. The company, meanwhile, said it expects its vehicle business to return to growth in 2025. Tesla also promised to launch new and &#8220;more affordable&#8221; models in the first half of 2025, in addition to other promises regarding the deployment of autonomous vehicles and licensing of the company&#8217;s full self-driving (FSD) driver assistance software to rivals.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>CARGO Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) shares fell 74.3% to $3.39 in pre-market trading after the company announced it discontinued its FIRCE-1 Phase 2 study.</li>
<li>Nature&#8217;s Sunshine Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) dipped 46.6% to $8.00 in pre-market trading.</li>
<li>Silexion Therapeutics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares fell 32.4% to $2.12 in pre-market trading. Silexion Therapeutics announced exercise of warrants for $3.3 million gross proceeds.</li>
<li>Avalon Holdings Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AWX#NYSE">AWX</a>) fell 19.2% to $2.90 in today's pre-market trading.</li>
<li>Coincheck Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNCK#NASDAQ">CNCK</a>) shares dipped 17.1% to $7.00 in pre-market trading after falling 4% on Wednesday.</li>
<li>Varex Imaging Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VREX#NASDAQ">VREX</a>) shares tumbled 12.2% to $11.94 in pre-market trading. Varex Imaging will report unaudited financial results for the first quarter of fiscal year 2025 following the close of regular trading on Thursday, Feb. 6.</li>
<li>Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) fell 10.6% to $116.00 in pre-market trading after the company reported worse-than-expected fourth-quarter revenue results and issued FY25 guidance below estimates.</li>
<li>ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) fell 9.4% to $1,035.79 in pre-market trading after the company reported worse-than-expected quarterly revenue results.</li>
<li>Orthofix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) declined 9.1% to $17.01 in pre-market trading. Orthofix Medical will release its fourth quarter and full-year 2024 financial results on Tuesday, Feb. 25, before the opening bell.</li>
<li>First Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBNC#NASDAQ">FBNC</a>) fell 6.8% to $41.00 in pre-market trading following fourth-quarter earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43300989/jim-cramer-this-industrial-stock-is-absolutely-terrific-first-solar-is-very-inexpensive">Jim Cramer: This Industrial Stock Is &#8216;Absolutely Terrific&#8217;, First Solar Is &#8216;Very Inexpensive&#8217;</a></li>
</ul>

Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Canaccord Genuity initiated coverage on Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>), a medical device company focused on the development, manufacture and commercialization of technology for the surgical treatment of spinal and broader orthopedic disorders.
Canaccord Genuity analyst Caitlin Cronin writes that over two years have passed since Orthofix merged with SeaSpine. With a new management team in place since early 2024, the company has successfully integrated the two teams and portfolios.
It is now ready to move forward with its long-term plan and unified strategy. The analyst is optimistic about Orthofix Medical&#8217;s unique offerings and plans for ongoing innovation, using its entire portfolio to drive growth across its various segments.
This cohesion is helping Orthofix Medical not only aim for above-market growth but also focus on cash generation and improve profit margins.
Canaccord Genuity has initiated with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/OFIX/analyst-ratings" rel="noreferrer noopener">price forecast of $24</a>.
The analyst Cronin adds that both 7D and ortho sub-segments are in Orthofix Medical&#8217;s highest growing markets, with the company estimating market growth of 10-12% in enabling tech and 5-6% in its ortho segment.
Overall, the company is targeting profitable growth. Additionally, Orthofix Medical&#8217;s current valuation appears attractive, trading well below the average of its small-cap and spine industry peers.
Third quarter 2024 net sales increased 7% year-over-year to $196.6 million, with 18% growth in U.S. Spine Fixation net sales driven by distribution expansion and further penetration in existing accounts, 9% growth in Bone Growth Therapies net sales and <a href="https://www.benzinga.com/pressreleases/24/11/b41802749/orthofix-reports-third-quarter-2024-results-reiterates-full-year-2024-financial-guidance-and-intro" target="_blank" rel="noreferrer noopener">13% growth in BGT Fracture net sales</a>.
The company expects 2024 sales of $795 million-$800 million compared to the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $796.6 million</a>.
The company sees adjusted EBITDA guidance of $64 million to $69 million and expects positive free cash flow for the second half of 2024.
Price Action: OFIX stock is down 0.05% at $18.35 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/01/43136830/lockheed-martin-secures-270-million-us-air-force-deal" target="_blank" rel="noreferrer noopener">Lockheed Martin Secures $270 Million US Air Force Deal For Next-Gen F-22 Infrared Defense</a></li>
</ul>
Image: Shutterstock

Analyst Color

Health Care

Initiation

General

This Analyst Says Orthopedic-Focused Orthofix Medical Is Positioned For Growth

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Canaccord Genuity analyst Caitlin Burrows initiated coverage on Orthofix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Buy rating and announced a price target of $24. Orthofix Medical shares closed at $18.36 on Tuesday. <a href="https://www.benzinga.com/quote/OFIX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst James Kirby initiated coverage on Sun Country Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNCY#NASDAQ">SNCY</a>) with an Overweight rating and announced a price target of $23. Sun Country Airlines shares closed at $16.63 on Tuesday. <a href="https://www.benzinga.com/quote/SNCY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Lizzie Dove initiated coverage on Viking Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) with a Neutral rating and announced a price target of $49. Viking Holdings shares closed at $48.49 on Tuesday. <a href="https://www.benzinga.com/quote/VIK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel analyst James Condulis initiated coverage on Cytokinetics, Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy rating and announced a price target of $80. Cytokinetics shares closed at $45.82 on Tuesday. <a href="https://www.benzinga.com/quote/CYTK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Gil Blum initiated coverage on Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) with a Buy rating and announced a price target of $9. Absci shares closed at $3.22 on Tuesday. <a href="https://www.benzinga.com/quote/ABSI/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CYTK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22070309/image-149-1024x592.png" alt="" class="wp-image-744560" style="width:540px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22070309/image-149-1024x592.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22070309/image-149-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22070309/image-149-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/22070309/image-149.png 1128w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43119868/netflix-procter-gamble-and-3-stocks-to-watch-heading-into-wednesday">Netflix, Procter &amp; Gamble And 3 Stocks To Watch Heading Into Wednesday</a></li>
</ul>

ABSI

CYTK

SNCY

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Canaccord Genuity analyst Caitlin Burrows initiates coverage on Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Buy rating and announces Price Target of $24.

Canaccord Genuity Initiates Coverage On Orthofix Medical with Buy Rating, Announces Price Target of $24

Shares of Versus Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VS#NASDAQ">VS</a>) rose sharply in today's pre-market trading after the company announced expansion into the Brazilian market as part of its strategy to grow its <a href="https://www.benzinga.com/quote/VS/news">international footprint</a>.
Versus Systems shares jumped 71.2% to $3.39 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>iSpecimen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) gained 49.1% to $4.25 in pre-market trading after the company announced it secured a supplier for hMPV biospecimens.</li>
<li>Nukkleus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) rose 33% to $27.30 in pre-market trading after the company announced it resolved its Nasdaq delisting notice and is now achieving compliance with the listing standards.</li>
<li>Signing Day Sports, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGN#NYSE">SGN</a>) rose 19.2% to $2.55 in pre-market trading after declining 9% on Thursday.</li>
<li>uCloudlink Group Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCL#NASDAQ">UCL</a>) gained 18.7% to $1.59 in pre-market trading. uCloudlink Group announced that it recently signed a cooperation agreement with WH Smith PLC&#8217;s InMotion Entertainment Group.</li>
<li>Treasure Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) gained 15.3% to $0.2471 in pre-market trading after gaining around 7% on Thursday.</li>
<li>TXNM Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TXNM#NYSE">TXNM</a>) gained 14.3% to $55.99 in pre-market trading.</li>
<li>Treace Medical Concepts, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMCI#NASDAQ">TMCI</a>) gained 14% to $9.40 in pre-market trading. On Monday, Treace announced preliminary, unaudited fourth quarter and full-year 2024 revenue.</li>
<li>LSI Industries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYTS#NASDAQ">LYTS</a>) rose 8.8% to $21.00 in pre-market trading. LSI Industries will issue fiscal 2025 second quarter results before the opening bell on Thursday, Jan. 23, 2025.</li>
<li>Orthofix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) gained 8.1% to $19.39 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Beasley Broadcast Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBGI#NASDAQ">BBGI</a>) fell 43.8% to $5.00 in pre-market trading.</li>
<li>Viavi Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIAV#NASDAQ">VIAV</a>) shares fell 19.3% to $8.10 in pre-market trading. Viavi Solutions will announce its fiscal second quarter 2025 financial results on Thursday, Jan. 30, 2025, after the close of market.</li>
<li>FOXO Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#NYSE">FOXO</a>) fell 18.4% to $0.2566 in pre-market trading after gaining 58% on Thursday.</li>
<li>Nature&#8217;s Sunshine Products, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NATR#NASDAQ">NATR</a>) shares dipped 15.9% to $12.00 in pre-market trading.</li>
<li>Elicio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) shares tumbled 12.8% to $5.61 in pre-market trading.</li>
<li>G. Willi-Food International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WILC#NASDAQ">WILC</a>) shares fell 11.5% to $14.01 in pre-market trading.</li>
<li>Bicara Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAX#NASDAQ">BCAX</a>) fell 11.5% to $10.51 in today's pre-market trading after declining 8% on Thursday.</li>
<li>J.B. Hunt Transport Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) declined 10.3% to $167.00 in pre-market trading as the company reported weaker-than-expected earnings for its fourth quarter on Thursday.</li>
<li>MiMedx Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) dipped 6.3% to $8.50 in pre-market trading.</li>
<li>Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) fell 5% to $12.60 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43049593/slb-jb-hunt-transport-and-3-stocks-to-watch-heading-into-friday">SLB, J.B. Hunt Transport And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>

Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket

WIIM

Orthofix Medical shares are trading higher after the company reported better-than-expected Q3 financial results and entered into a new-credit agreement worth up to $275 million. Additionally, Stifel upgraded the stock from Hold to Buy and raised its price target from $18 to $24 while Roth MKM raised its price target from $20 to $22.

Roth MKM analyst Jason Wittes reiterates Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) with a Buy and raises the price target from $20 to $22.

Roth MKM Reiterates Buy on Orthofix Medical, Raises Price Target to $22

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Piper Sandler boosted The Trade Desk, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) price target from $110 to $140. Piper Sandler analyst Matt Farrell reiterated an Overweight rating. Trade Desk shares closed at $132.53 on Wednesday. See how other analysts view this stock.</li>
<li>Scotiabank raised the price target for Cloudflare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) from $85 to $87. Scotiabank analyst Patrick Colville maintained a Sector Perform rating. Cloudflare shares closed at $95.66 on Thursday. <a href="https://www.benzinga.com/quote/NET/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo raised the price target for Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) from $19 to $41. Wells Fargo analyst Stan Berenshteyn upgraded the stock from Underweight to Equal-Weight. Doximity shares closed at $43.42 on Thursday. <a href="https://www.benzinga.com/quote/DOCS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird cut Yelp Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YELP#NYSE">YELP</a>) price target from $39 to $37. Baird analyst Colin Sebastian maintained a Neutral rating. Yelp shares settled at $36.37 on Thursday. <a href="https://www.benzinga.com/quote/YELP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group raised Lowe&#8217;s Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) price target from $275 to $305. Telsey Advisory Group analyst Joseph Feldman upgraded the stock from Market Perform to Outperform. Lowe&#8217;s shares closed at $266.30 on Thursday. <a href="https://www.benzinga.com/quote/LOW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird boosted Fortinet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) price target from $80 to $88. Baird analyst Shrenik Kothari maintained an Outperform rating. Fortinet shares closed at $83.68 on Thursday. <a href="https://www.benzinga.com/quote/FTNT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup raised the price target for Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) from $28 to $40. Citigroup analyst Steven Zaccone upgraded the stock from Neutral to Buy. Chewy shares settled at $30.79 on Thursday. <a href="https://www.benzinga.com/quote/CHWY/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler raised Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) price target from $230 to $280. Piper Sandler analyst Brent Bracelin maintained an Overweight rating. Veeva shares closed at $223.39 on Thursday. <a href="https://www.benzinga.com/quote/VEEV/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Stifel raised the price target for Orthofix Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) from $18 to $24. Stifel analyst Mathew Blackman upgraded the stock from Hold to Buy. Orthofix Medical shares closed at $18.22 on Thursday. <a href="https://www.benzinga.com/quote/OFUX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird increased Under Armour, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) price target from $8 to $10. Baird analyst Jonathan Komp maintained a Neutral rating. Under Armour shares closed at $11.13 on Thursday. <a href="https://www.benzinga.com/quote/UAA/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/11/41820056/how-to-earn-500-a-month-from-nvidia-stock-after-trump-win">How To Earn $500 A Month From Nvidia Stock After Trump Win</a></li>
</ul>

CHWY

DOCS

FTNT

VEEV

YELP

Lowe's To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Friday

Stifel analyst Mathew Blackman upgrades Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) from Hold to Buy and raises the price target from $18 to $24.

Upgrades

Stifel Upgrades Orthofix Medical to Buy, Raises Price Target to $24

Financing

Orthofix Medical Announced The Entry Into A New Credit Agreement Providing The Company With Up To $275M In A Senior-secured Term Loan With A 48-month Interest Only Period

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) affirms FY2024 sales outlook from $795.00 million-800.00 million to $795.00 million-800.00 million.

Orthofix Medical Affirms FY2024 Sales Guidance from $795.00M-800.00M to $795.00M-800.00M

Orthofix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.15) by 146.67 percent. The company reported quarterly sales of $196.606 million which beat the analyst consensus estimate of $196.522 million by 0.04 percent. This is a 6.85 percent increase over sales of $184.006 million the same period last year.

Orthofix Medical Q3 2024 Adj. EPS $0.07 Beats $(0.15) Estimate, Sales $196.606M Beat $196.522M Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Forthofix.com%2F&amp;esheet=54125379&amp;newsitemid=20240923211580&amp;lan=en-US&amp;anchor=Orthofix+Medical+Inc&amp;index=1&amp;md5=f980520f95bd1a9234c20487cdf8b284">Orthofix Medical Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OFIX#NASDAQ">OFIX</a>), a leading global medical technology company, today announced the presentation of new data supporting the use of Orthofix's proprietary Pulsed Electromagnetic Field (PEMF) stimulation to increase fusion rates as an adjunct to lumbar spine fusion surgery. Patients treated with the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fbonegrowththerapy.com%2Ftherapies%2Fspinal-fusion%2Fspinalstim-lumbar-fusion%2F&amp;esheet=54125379&amp;newsitemid=20240923211580&amp;lan=en-US&amp;anchor=SpinalStim&amp;index=2&amp;md5=c26f0cc0fb348022b3ce0b675596e790">SpinalStim</a>&#x2122; bone growth therapy device demonstrated a high rate of successful fusion with significant improvements in pain, function and quality of life, despite having risk factors for pseudarthrosis.
The abstract will be presented by Dr. Marc Weinstein, an orthopedic spine surgeon at the Florida Orthopaedic Institute in Tampa, Florida, at the North American Spine Society (NASS) Annual Meeting in Chicago, IL, on September 25, during the Research and Innovation Showcase in the McCormick Place West Lobby of the McCormick Convention Center.
During the NASS annual meeting, Orthofix is also highlighting a variety of new products including the full market launch of OsteoStrand&#x2122; Plus C. A 100% bone-derived graft, OsteoStrand Plus C is comprised of Demineralized Bone Matrix (DBM) fibers and Accell&#x2122; Bone Matrix, a dispersed form of DBM that provides immediate release of growth factors upon implantation and increases the concentration of growth factors in the product, and cancellous chips. Used as a bone graft material in fusion applications, the OsteoStrand Plus C features improved graft packability relative to non-chip containing options – for a denser fill and to ensure minimal graft displacement. Additionally, Orthofix is announcing the launch of the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fm6disc.com%2F&amp;esheet=54125379&amp;newsitemid=20240923211580&amp;lan=en-US&amp;anchor=M6-C&amp;index=3&amp;md5=0f2300dfde3b2d3c8390c084ccf90edc">M6-C</a>&#x2122; Single-Use, Disposable Instrumentation sets, the first FDA-cleared, single-use, disposable instruments designed specifically for cervical disc arthroplasty.

Orthofix Unveils New Spinal Fusion Products and Data, Highlighting Innovation at NASS Annual Meeting

Orthofix Sees 2024 Net Sales $795M-$800M vs $793.79M Est.

Press Releases

Orthofix Announces New Term Loan

OFIX INVESTORS: OrthoFix Medical Inc. Stockholders Should Contact Robbins LLP About Joining the Pending OFIX Class Action

Legal

OFIX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Orthofix Medical Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Orthofix to Participate in Upcoming Investor Conferences

DexCom, Orthofix, Spire Global, and Moderna Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

Dexcom, Orthofix, Spire Global, and Target Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

Orthofix to Report Fourth Quarter and Full-Year 2024 Financial Results

Orthofix to Participate in the Canaccord Genuity 2025 Musculoskeletal Conference

Orthofix Reports Fourth Quarter and Full-Year 2024 Results and Provides 2025 Financial Guidance

Comments

Orthofix Medical

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL